Wang Da, Nagle Peter W, Wang Helena H, Smit Justin K, Faber Hette, Baanstra Mirjam, Karrenbeld Arend, Chiu Roland K, Plukker John Th M, Coppes Robert P
Department of Biomedical Sciences of Cells and Systems, Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
Cancers (Basel). 2019 Jun 13;11(6):821. doi: 10.3390/cancers11060821.
Esophageal cancer (EC) is an aggressive disease with a poor prognosis. Treatment resistance is a major challenge in successful anti-cancer therapy. Pathological complete response after neoadjuvant chemoradiation (nCRT) is low, thus requiring therapy optimization. The Hedgehog (HH) pathway has been implicated in therapy resistance, as well as in cancer stemness. This article focusses on the HH pathway as a putative target in the treatment of EC. Immunohistochemistry on HH members was applied to EC patient material followed by modulation of 3D-EC cell cultures, fluorescence-activated cell sorting (FACS), and gene expression analysis after HH pathway modulation. Sonic Hedgehog (SHH) and its receptor Patched1 (PTCH1) were significantly enriched in EC resection material of patients with microresidual disease (mRD) after receiving nCRT, compared to the control group. Stimulation with SHH resulted in an up-regulation of cancer stemness in EC sphere cultures, as indicated by increased sphere formation after sorting for CD44+/CD24- EC cancer stem-like cell (CSC) population. On the contrary, inhibiting this pathway with vismodegib led to a decrease in cancer stemness and both radiation and carboplatin resistance. Our results strengthen the role of the HH pathway in chemoradiotherapy resistance. These findings suggest that targeting the HH pathway could be an attractive approach to control CSCs.
食管癌(EC)是一种侵袭性疾病,预后较差。治疗耐药性是成功抗癌治疗的主要挑战。新辅助放化疗(nCRT)后的病理完全缓解率较低,因此需要优化治疗方案。刺猬(HH)信号通路与治疗耐药性以及癌症干性有关。本文重点探讨HH信号通路作为EC治疗的潜在靶点。对EC患者材料进行HH成员的免疫组织化学检测,随后对3D-EC细胞培养进行调控、荧光激活细胞分选(FACS)以及HH信号通路调控后的基因表达分析。与对照组相比,在接受nCRT后有微残留疾病(mRD)的患者的EC切除材料中,音猬因子(SHH)及其受体 patched1(PTCH1)显著富集。用SHH刺激导致EC球状体培养物中癌症干性上调,这通过对CD44+/CD24-EC癌症干细胞样细胞(CSC)群体进行分选后球状体形成增加来表明。相反,用维莫德吉抑制该信号通路导致癌症干性以及放疗和卡铂耐药性降低。我们的结果强化了HH信号通路在放化疗耐药中的作用。这些发现表明,靶向HH信号通路可能是控制癌症干细胞的一种有吸引力的方法。